Key Points
- Insider sale: Director James Hamilton sold 10,000 shares at an average price of $64.19 on March 5 for $641,900, reducing his stake by 4.05% to 236,958 shares, per an SEC filing.
- Mixed quarter: Arrowhead missed EPS expectations ($0.22 vs. $0.60 consensus) but beat revenue forecasts with $264.03 million, a roughly 10,461% year‑over‑year increase.
- Analyst outlook: The stock carries a MarketBeat consensus of Moderate Buy with a consensus target of $81.67, while some brokers have raised targets as high as $110.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James Hamilton sold 10,000 shares of the business's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $64.19, for a total transaction of $641,900.00. Following the transaction, the insider owned 236,958 shares of the company's stock, valued at $15,210,334.02. This trade represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Arrowhead Pharmaceuticals Stock Performance
Shares of ARWR opened at $60.67 on Tuesday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $76.76. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. The company has a market cap of $8.50 billion, a PE ratio of 39.65 and a beta of 1.23. The stock has a 50-day moving average price of $65.28 and a 200-day moving average price of $50.57.
Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). The company had revenue of $264.03 million during the quarter, compared to analysts' expectations of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm's revenue was up 10461.3% on a year-over-year basis. During the same quarter last year, the firm posted ($1.39) earnings per share. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have issued reports on ARWR shares. HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 10th. Bank of America increased their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a "buy" rating in a research note on Tuesday, December 9th. Chardan Capital raised their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. Piper Sandler reaffirmed an "overweight" rating and issued a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Finally, Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $81.67.
Check Out Our Latest Research Report on Arrowhead Pharmaceuticals
Institutional Trading of Arrowhead Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. Marex Group plc bought a new stake in Arrowhead Pharmaceuticals during the second quarter valued at about $576,000. Nordea Investment Management AB increased its position in Arrowhead Pharmaceuticals by 74.5% in the third quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company's stock worth $12,661,000 after buying an additional 158,937 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company's stock worth $34,065,000 after buying an additional 2,096,238 shares during the period. HBK Sorce Advisory LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $2,823,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $287,000. Hedge funds and other institutional investors own 62.61% of the company's stock.
About Arrowhead Pharmaceuticals
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company's pipeline includes multiple candidates in various stages of development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
